A review with 12 referencesMonoclonal antibodies have numerous potential applications as therapeutics.As target-specific drugs, they are expected to cause fewer side effects than many treatments for cancer and other diseases.However, immunogenicity has been a significant barrier to clin. success.Several routes of mol. engineering are being explored to prevent immune response to monoclonal antibodies in patients, and the best way has yet to be proven.